of ovarian cancers are this one type - it begins in the Fallopian tube, not the ovary, and it causes most ovarian cancer deaths.
The evidence, in plain language
Six findings, six pictures. The studies behind each are one tap away.
Three quarters of ovarian cancer is one disease - high-grade serous - and it starts at the open end of the Fallopian tube.
Read the studies behind this
Most aggressive ovarian cancers begin in the Fallopian tubes
Pathology studies of Fallopian tubes removed from women at high inherited risk found the earliest cancer changes in the end of the tube, and molecular studies matched later ovarian tumors to those tubal precursors. That is why removing the tubes - while keeping the ovaries and their hormones - prevents most of these cancers.
Summarized in the European Society of Gynaecological Oncology (ESGO) consensus statements on salpingectomy.There is no reliable screening test
Unlike breast, cervical, or colorectal cancer, ovarian cancer has no screening test that reduces deaths. Most cases are found at an advanced stage. Prevention during surgery that is already happening is currently the most practical way to lower risk for average-risk women.
Basis of the prevention-first approach adopted by the Michigan program.Prefer a national overview? MI-MAGIC’s partner Outsmart Ovarian Cancer explains this science for patients, with fact sheets and videos.
More than half of women who develop ovarian cancer had an operation years, or even decades, earlier when their Fallopian tubes could have been removed.
Twenty women diagnosed with ovarian cancer, one per row
Median gap: 30 years
50years earlier40302010diagnosis
Read the studies behind this
More than half of patients had a prior surgery where the Fallopian tubes could have been removed
In a review of 605 women treated for high-grade serous ovarian cancer, 56.5% (342 of 605) had undergone an earlier abdominal or pelvic operation where both Fallopian tubes could have been removed. The median time between that operation and the cancer diagnosis was 30 years - a long window in which prevention was possible.
About 59% of those missed opportunities were gynecologic operations and 35% were general surgery. Among the general-surgery cases, gallbladder removal was the most common (53.4%) - and about 636,000 gallbladder removals were performed in US women in 2019 alone. This is why MI-MAGIC works across surgical specialties instead of within gynecology only.
Tischer et al., Gynecologic Oncology, 2025.The eligible population is large
Roughly 470,000 to 513,000 US women each year undergo gallbladder, ventral hernia, or bariatric surgery where Fallopian tube removal could be offered. Modeling suggests broad adoption could reduce ovarian cancer incidence by 20 to 23%, and 81% of surveyed patients found the option acceptable.
Cook et al., Gynecologic Oncology Reports, 2025.Removing both Fallopian tubes cuts the risk at least in half.
Lifetime ovarian cancer risk per 1,000 women
The newest British Columbia data suggest more: a 78% drop.
Read the studies behind this
Roughly 65% lower risk in national cohort data
In a Swedish national cohort, women who had both Fallopian tubes removed had about a 65% lower rate of ovarian cancer than women who did not (hazard ratio 0.35, 95% confidence interval 0.17 to 0.73). Across studies, estimates range from 49% to 77%.
Patient materials on this site deliberately use the more conservative phrasing "cuts the risk at least in half - from about 11 in 1,000 to about 5 in 1,000."
Falconer et al., JNCI, 2015; Yoon et al. meta-analysis, 2016.Zero serous cancers observed after 25,889 opportunistic salpingectomies
British Columbia has tracked opportunistic salpingectomy at the population level since 2010. Among 25,889 women who had the procedure, no serous ovarian cancers were observed during follow-up, where 5.27 were statistically expected. Follow-up is still relatively short, so these figures will keep maturing.
Hanley et al., JAMA Network Open, 2022.78% lower serous cancer risk with longer follow-up
The updated British Columbia analysis, with more women and longer follow-up, found a 78% lower rate of serous ovarian cancer after opportunistic salpingectomy (hazard ratio 0.22, 95% confidence interval 0.05 to 0.95) - and the few cancers that did occur after Fallopian tube removal were rarely the high-grade serous type.
Sowamber et al., JAMA Network Open, 2026.When researchers look at outcomes over a longer period, fewer operations are needed to prevent one case of ovarian cancer.
Operations per cancer prevented, for women having surgery at 50 to 54 - lower is better
Procedures needed to prevent one cancer - shorter bar means fewer
Read the studies behind this
The full age table
"Number needed to treat" (NNT) is how many people must receive a procedure for one of them to avoid the disease. Lower numbers mean more efficient prevention.
| Age at surgery | Over 10 years | Over 20 years | Over 30 years |
|---|---|---|---|
| 40-44 | 1,441 | 522 | 286 |
| 45-49 | 1,014 | 413 | 240 |
| 50-54 | 801 | 349 | 212 |
| 55-59 | 676 | 304 | 201 |
| 60-64 | 590 | 274 | 202 |
| 65-69 | 517 | 266 | Not reported |
In the same range as screening colonoscopy
Roughly 200 to 300 opportunistic salpingectomies prevent one ovarian cancer over a 20 to 30 year horizon, falling toward 150 over a lifetime. For comparison, in the NordICC randomized trial a single screening colonoscopy needed about 455 invitations (roughly 100 to 150 among those actually screened) to prevent one colorectal cancer over 10 to 13 years. The difference: salpingectomy adds minutes to an operation already underway, with no separate procedure, anesthesia, or recovery.
Wright et al., Annals of Surgery, 2025; Bretthauer et al. (NordICC), NEJM, 2022, with 13-year follow-up.Adding the procedure has not been shown to add harm - and the ovaries keep doing their job.
women tracked in British Columbia since 2010 - the largest safety experience anywhere.
serous ovarian cancers found in that group afterward, where 5.27 were expected.
average added time in the operating room.
chance of injury from the added step. Hormones and menopause: unchanged.
Read the studies behind this
The safety record in detail
Population studies found no increase in complications, transfusions, readmissions, or repeat operations when salpingectomy was added. Added operative time averaged 13 minutes at gallbladder surgery (range 4 to 45), about 4 minutes in British Columbia colorectal data, and 0 to 16 minutes at hysterectomy. Organ injury during the salpingectomy step occurred in fewer than 5 of 7,434 operations. The ovaries stay, and studies comparing women with and without Fallopian tube removal found no difference in hormone function or age at menopause.
Hanley et al., 2018, 2020, and 2022; Tomasch et al., 2020; British Columbia population data.Preventing a cancer costs the health system less than treating one.
saved per operation over a lifetime - preventing a cancer costs less than treating one.
Read the studies behind this
Modeled as cost-saving, not just cost-effective
A 2026 economic model of opportunistic salpingectomy across six common operations found it saved an average of $2,176 per procedure over a lifetime, by preventing cancers that are expensive to treat. It produced better outcomes at lower cost in more than 99% of 10,000 simulations. An earlier model of salpingectomy at gallbladder surgery estimated $11,000 to $26,000 per quality-adjusted life year - well within accepted thresholds.
Adjei et al., 2026; Matsuo et al., 2022; Kather et al., PLOS Medicine, 2025.What do professional societies recommend?
Professional bodies on four continents have endorsed opportunistic salpingectomy over the past fifteen years, each widening the circle.
- 2011Canada - GOC
Canada's cancer surgeons said it first: if you are already having gynecologic surgery, removing the Fallopian tubes is worth a conversation.
- 2013United States - SGO
US cancer surgeons agreed - and added: consider it in place of “getting your tubes tied.”
- 2015ACOG - America's OB-GYNs
“The surgeon and patient should discuss the potential benefits of the removal of the fallopian tubes.”
Updated and strengthened in 2019. The UK and Australia issued similar guidance.
- 2026Europe - ESGO
“Clinicians should include this prevention intervention in preoperative counseling of eligible women.”
In plain terms: your surgical team should bring it up - now including operations like appendix and bowel.
Swipe to travel the timeline.
Read the studies behind this
ACOG: two guidelines, one for each risk group
For women at average risk having pelvic surgery for benign disease, Committee Opinion 774 (2019, which replaced Committee Opinion 620 of 2015) supports opportunistic salpingectomy: safe at hysterectomy or as the method of sterilization - no increase in transfusions, readmissions, complications, infections, or fever - with no apparent effect on ovarian function, and worth discussing with every patient who desires permanent sterilization.
For women at hereditary or otherwise increased risk (BRCA1/2 and related syndromes), a different guideline governs: Practice Bulletin 182, with its own pathway of genetic counseling and more protective risk-reducing surgery. That split is exactly why this website routes patients with a strong family history or a known variant to genetic counseling instead of opportunistic salpingectomy.
ACOG Committee Opinion No. 774, 2019; ACOG Practice Bulletin No. 182, Hereditary Breast and Ovarian Cancer Syndrome, 2017.The earlier statements
Society of Gynecologic Oncology of Canada statement, 2011; SGO clinical practice statement, 2013; RCOG and RANZCOG endorsements reviewed in Tomasch et al., 2020.
ESGO: consider it at selected non-gynecologic operations too
The European Society of Gynaecological Oncology reviewed 230 studies and reached consensus on 18 statements, each with more than 75% agreement: opportunistic salpingectomy is significantly associated with lower tubo-ovarian cancer risk, has no adverse short-term effect on ovarian function, is safe across surgical approaches with little added time, and is feasible during both gynecological and non-gynecological procedures.
Piek et al. (ESGO consensus statements), JAMA, 2026.The research library
The key publications behind the program, each linked to its journal record.
Prophylactic salpingectomy at elective laparoscopic cholecystectomy
First proof general surgeons can perform it: 93% completion, 13 minutes added, no attributable complications.
Outcomes from opportunistic salpingectomy for ovarian cancer prevention
25,889 BC patients: zero serous ovarian cancers observed where 5.27 were expected.
Serous ovarian cancer following opportunistic bilateral salpingectomy
Updated BC data with longer follow-up: 78% lower serous cancer risk (HR 0.22).
Quantifying opportunities to reduce high-grade serous ovarian cancer
56.5% of patients had a prior surgical opportunity, a median of 30 years before diagnosis.
Potential of opportunistic salpingectomy at non-gynecologic surgery
About half a million eligible US women per year; potential 20-23% incidence reduction; 81% patient acceptance.
Population-level reduction through salpingectomy at cholecystectomy
NNT by age and horizon; up to 850 lifetime cancers prevented at 40% adoption.
The ESGO consensus statements on opportunistic salpingectomy (JAMA)
18 evidence-based statements: effective, safe across approaches, minimal added time; consider at gynecologic and selected non-gynecologic surgery.
ACOG Committee Opinion No. 774: opportunistic salpingectomy for ovarian cancer prevention
US guidance: safe at hysterectomy and as the method of sterilization; discuss with every patient desiring permanent sterilization.
Cost-effectiveness across six abdominopelvic procedures
Cost-saving in over 99% of simulations: $2,176 saved per procedure over a lifetime.
Cost-effectiveness modeling across abdominal surgeries (Germany)
Could prevent 15% of ovarian cancer cases; extending beyond gynecology yields 3.5 times more eligible operations.
Leveraging non-gynecologic surgeries for prevention (editorial)
Implementation priorities: coordination, counseling and consent, coding, and health equity.
Review status, named reviewers, and the maintained reference list live on the clinical review page. For patient-friendly summaries of the same science, visit the Outsmart Ovarian Cancer resource library ↗.